Laguna Treatment Hospital Awarded $100,000 Grant to Combat Opioid Crisis
When it comes to opioid-related overdose deaths in California, Orange County ranks among the top 20 counties in the state with the highest rates, with 255 deaths in 2017 alone. For Laguna Treatment Hospital, Orange County’s first chemical dependency recovery hospital, these statistics are a call to action. The hospital was recently awarded a $100,000 grant from the Center at Sierra Health Foundation via the California Department of Health Care Services to enhance its medication-assisted treatment (MAT) services to combat the opioid crisis.
“Medication-assisted therapy is the gold standard of care for opioid use disorder, yet in Orange County there is a shortage of community resources that offer this treatment once someone leaves the hospital,” said Bob Hails, Laguna Treatment Hospital CEO. “We want the community to know they can turn to us for help. This grant will help us to do even more to support those struggling with addiction.”
As a best practice, Laguna Treatment Hospital offers medication-assisted therapy for every level of care, from detox, inpatient rehabilitation and residential treatment to partial hospitalization and intensive outpatient services. With the grant, the hospital plans to develop new MAT services, increase localized treatment of opioid use disorder and make facility improvements to enhance medication management and patient privacy areas.
With San Diego county within a short driving distance, the hospital hopes to serve patients from that community as well. The county also ranks in the top 20 for its opioid-related overdose death rate.
“To be a part of this statewide initiative to build a growing network of MAT services is a critical step forward in saving lives,” said Hails.
Forward Looking Statements
This release contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are made only as of the date of this release. In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “may,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” and similar expressions intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements may include information concerning AAC Holdings, Inc.’s (collectively with its subsidiaries; “AAC Holdings” or the “Company”) possible or assumed future results of operations, including descriptions of the Company’s revenue, profitability, outlook and overall business strategy. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results and performance to be materially different from the information contained in the forward-looking statements. These risks, uncertainties and other factors include, without limitation: (i) the Company’s inability to effectively operate its facilities; (ii) the Company’s reliance on its sales and marketing program to continuously attract and enroll clients; (iii) a reduction in reimbursement rates by certain third-party payors for inpatient and outpatient services and point-of-care and definitive lab testing; (iv) the Company’s failure to successfully achieve growth through acquisitions and de novo projects; (v) risks associated with estimates of the value of accounts receivable or deterioration in collectability of accounts receivable; (vi) a failure to achieve anticipated financial results from contemplated and prior acquisitions; (vii) the possibility that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of an acquisition; (viii) the Company’s failure to achieve anticipated financial results from contemplated and prior acquisitions; (ix) a disruption in the Company’s ability to perform diagnostic laboratory services; (x) maintaining compliance with applicable regulatory authorities, licensure and permits to operate the Company’s facilities and laboratories; (xi) a disruption in the Company’s business and reputational and economic risks associated with the civil securities claims brought by shareholders or claims by various parties; (xii) inability to meet the covenants in the Company’s loan documents or lack of borrowing capacity; and (xiii) general economic conditions, as well as other risks discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 and other filings with the Securities and Exchange Commission. As a result of these factors, we cannot assure you that the forward-looking statements in this release will prove to be accurate. Investors should not place undue reliance upon forward-looking statements.